Clene Announces Strong Biomarker Data for ALS Drug CNM-Au8, Secures Key FDA Meeting for Accelerated Approval Pathway

summarizeSummary

Clene Inc. announced new positive biomarker data for its ALS drug candidate, CNM-Au8, demonstrating a link between NfL and IGFBP7 reductions and improved survival. The company has secured an in-person Type C meeting with the FDA to discuss these findings and potential accelerated approval pathways.

check_boxKey Events

• FDA Type C Meeting Granted

  Clene will hold an in-person Type C meeting with the U.S. Food and Drug Administration (FDA) in the first quarter of 2026 to discuss the regulatory pathway for CNM-Au8.

• NfL Biomarker Data Supports Accelerated Approval

  New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) reductions in neurofilament light chain (NfL) are significantly associated with lower mortality risk, supporting NfL reduction as a candidate surrogate endpoint for accelerated approval.

• IGFBP7 Decline Linked to Improved Survival

  New exploratory findings indicate that in responders with IGFBP7 biomarker decline, CNM-Au8 30mg was strongly associated with a 78% reduced mortality risk (HR 0.22, p=0.01) in the HEALEY ALS Platform Trial, consistent with emerging genetic evidence.

• Pre-Meeting Briefing Package Submitted

  Clene has submitted its pre-meeting briefing package to the FDA, addressing prior requests to establish the clinical significance, reproducibility, and link NfL decline to clinical outcomes, aiming to inform future regulatory pathways including potential accelerated approval.

auto_awesomeAnalysis

This filing highlights significant progress in Clene's efforts to secure FDA approval for CNM-Au8 for ALS. The new biomarker data, particularly the link between NfL and IGFBP7 reductions and improved survival, strengthens the case for the drug's efficacy. The FDA granting an in-person Type C meeting is a critical step, indicating the agency's willingness to engage in detailed discussions about the data and potential accelerated approval pathways. This development could significantly de-risk the regulatory path for CNM-Au8 and represents a major positive catalyst for the company, especially given the high unmet medical need in ALS. Investors should monitor the outcome of the FDA meeting for further clarity on the regulatory timeline.